More Kiwi scientists becoming business leaders and entrepreneurs
26 February 2019
The Maurice Wilkins Centre hosted a full-day workshop on 22 February 2019 at Victoria University of Wellington for young scientists keen to learn more about how to commercialise their work.
MWC collaboration solves elusive protein structure
17 May 2016
A collaboration between chemists and biologists from the Maurice Wilkins Centre has enabled researchers to solve the structure of a potent antimicrobial protein with potential to tackle bacterial diseases in kiwifruit vines.
Promising New Zealand compound selected as drug candidate for tuberculosis
17 September 2012
A New Zealand-designed compound that shows promise against treatment-resistance tuberculosis (TB) has been selected as a drug candidate by international non-profit drug developer the Global Alliance for TB Drug Development (TB Alliance).
Local cancer drug approved for first clinical trial in United States and New Zealand
30 August 2012
The US Food and Drug Administration (FDA) has granted approval for PR610, an anticancer “stealth” drug invented in New Zealand, to move forward to human clinical trials through its approval of an Investigational New Drug (IND) Application for the drug.
Second New Zealand anticancer “stealth” drug targeted for clinical development
4 August 2011
A second anticancer “stealth” drug designed by New Zealand scientists has been targeted for clinical development under a collaborative agreement between Proacta Incorporated (San Diego) and Yakult Honsha Co., Ltd. (Tokyo).
New Zealand cancer drug to commence clinical trials
13 June 2011
A novel cancer drug designed by scientists from The University of Auckland and Maurice Wilkins Centre for Molecular Biodiscovery, and licensed to university spin-out company Pathway Therapeutics, Inc., has received approval from the US Food and Drug Administration to enter c...
New Zealand-designed anti-tumour agent to enter clinical development
7 June 2011
A novel anti-tumour agent, CEN-209, created by New Zealand scientists will enter clinical development under two international agreements announced last week.
New class of anticancer ‘stealth’ drug proceeds to clinical development
23 February 2011
The first of an exciting new class of anti-cancer drugs designed in New Zealand will proceed to clinical development in the United States, following the announcement today of a deal between Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo).